Skip to main content
Premium Trial:

Request an Annual Quote

This Won't Hurt a Bit

Premium

Getting tested for bladder cancer — which involves the use of a catheter — can be rather invasive and somewhat painful, says Forbes' Peter Cohan. So biotech startup Predictive Biosciences says it has come up with a better way. The company has commercialized a urine-based, non-invasive cancer detection technology invented by two researchers that uses a combination of protein and DNA biomarkers to help clinicians diagnose bladder and prostate cancer, Cohan says. Because of the potential size of the target markets — a $3 billion bladder cancer detection market and a $3 billion prostate cancer detection market — Predictive Biosciences has raised $57 million in venture capital. The company doesn't sell its diagnostics to urologists, it does test urine samples from patients at its own lab, Cohan adds. The company acquired an anatomic pathology lab in Cleveland in January 2010, focused on urology.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.